gitogenin: an alpha-glucosidase inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 441887 |
| CHEMBL ID | 1770687 |
| CHEBI ID | 5363 |
| SCHEMBL ID | 23524443 |
| MeSH ID | M0060417 |
| Synonym |
|---|
| gitogenin |
| C08899 |
| 511-96-6 |
| digin |
| nsc-147752 |
| CHEMBL1770687 |
| chebi:5363 , |
| LMST01080010 |
| (25r)-5alpha-spirostan-2alpha,3beta-diol |
| unii-60zmy8ih51 |
| nsc 147752 |
| 5alpha,22alpha-spirostane-2alpha,3beta-diol |
| ai3-62266 |
| 5alpha-spirostan-2alpha,3beta-diol, (25r)- |
| spirostan-2,3-diol, (2alpha,3beta,5alpha,25r)- |
| 60zmy8ih51 , |
| AKOS016009639 |
| spirostan-2,3-diol, (2a,3b,5a,25r)- |
| AC-35113 |
| 5.alpha.,25d-spirostan-2.alpha.,3.beta.-diol |
| 2.alpha.-hydroxytigogenin |
| gitogenin [mi] |
| (2alpha,3|a,5alpha,25r)-spirostan-2,3-diol |
| digine |
| SCHEMBL23524443 |
| (25r,s)-5alpha-spirostane-2alpha,3beta-diol |
| HY-N2574 |
| CS-0022911 |
| Q5880476 |
| mfcd00273328 |
| (1r,2s,4s,5'r,6r,7s,8r,9s,12s,13s,15r,16r,18s)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane]-15,16-diol |
| A927966 |
| MS-27723 |
| DTXSID101023656 |
| Class | Description |
|---|---|
| triterpenoid | Any terpenoid derived from a triterpene. The term includes compounds in which the C30 skeleton of the parent triterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups). |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID594707 | Antifungal activity against Candida albicans ATCC 10231 assessed as reduction in growth after 48 hrs by broth microdilution method relative to control | 2011 | Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10 | Synthesis and antifungal activity of functionalized 2,3-spirostane isomers. |
| AID594709 | Antifungal activity against Cryptococcus neoformans ATCC 36556 assessed as reduction in growth after 48 hrs by broth microdilution method relative to control | 2011 | Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10 | Synthesis and antifungal activity of functionalized 2,3-spirostane isomers. |
| AID594706 | Antifungal activity against Candida glabrata ATCC 48435 assessed as reduction in growth after 48 hrs by broth microdilution method relative to control | 2011 | Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10 | Synthesis and antifungal activity of functionalized 2,3-spirostane isomers. |
| AID594708 | Antifungal activity against Aspergillus fumigatus ATCC 16424 reduction in growth after 48 hrs by broth microdilution method relative to control | 2011 | Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10 | Synthesis and antifungal activity of functionalized 2,3-spirostane isomers. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (20.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||